Table 1.
Patients with colorectal carcinoma (n = 297) and healthy donors (NHDs, n = 40) included in the study
| Patients, n = 297 | NHDs, n = 40 | |
|---|---|---|
| Gender | ||
| Males | 185 (62.3%) | 19 (50%)# |
| Females | 112 (37.7%) | 19 (50%)# |
| Age | ||
| Median | 67 years | 32 years |
| Range | 22–91 years | 22–51 years |
| sICAM-1 | ||
| < 290 ng/ml (sICAM-1low) | 208 (70.0%) | 33 (83%) |
| ≥ 290 ng/ml (sICAM-1high) | 89 (30.0%) | 7 (18%) |
| CEA | ||
| Normal (< 5 ng/ml) | 199 (67.0%) | |
| Elevated (≥ 5 ng/ml) | 98 (33.0%) | |
| UICC stages | ||
| Stage I | 61 (20.5%) | |
| Stage II | 111 (37.4%) | |
| Stage III | 63 (21.2%) | |
| Stage IV | 62 (20.9%) | |
| R classification | ||
| R0 | 246 (82.8%) | |
| R1 | 4 (1.3%) | |
| R2 | 40 (13.5%) | |
| RX | 7 (2.4%) | |
| Localization | ||
| Colon | 231 (77.8) | |
| Rectum | 66 (22.2) |
sICAM-1 soluble intercellular adhesion molecule-1, CEA carcinoembryonic antigen, UICC Union Internationale Contre le Cancer, R classification residual tumor classification
#Gender of two donors was not registered